0
Generics’ giant Mylan Laboratories was granted a US court order in September 2010 prohibiting Apotex, a Canadian pharma company, from selling paroxetine. The order also prohibits GlaxoSmithKline (GSK) from supplying Paxil CR (paroxetine extended-release tablets) to Apotex. Mylan has an exclusive agreement to sell a copy of GSK’s Paxil CR. If GSK were to authorise additional sales of generic paroxetine this would undercut sales and cause an “irretrievable loss of market share and customers” for generic Paxil CR, a Mylan spokesman said.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- EC approves eight biosimilars, six more await final authorization
- EMA recommends approval for three biosimilars: Jubereq, Osvyrti, and Qoyvolma
- FDA biosimilar approvals in March 2025: Bomyntra, Conexxence, and Omlyclo
- Canada approves pegfilgrastim biosimilar Pexegra
- MORE EDITORIAL SECTIONS
- Search
Post your comment